Understanding SGLT2 Inhibitors and Their Role in Kidney Health

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have reshaped the management of type 2 diabetes and, more recently, the treatment of chronic kidney disease (CKD). Originally developed to lower blood glucose by promoting urinary glucose excretion, these medications now stand as a pillar of cardiorenal protection. Large-scale randomized trials have demonstrated that SGLT2 inhibitors reduce the risk of kidney failure, slow the decline of estimated glomerular filtration rate (eGFR), and decrease proteinuria in patients with and without diabetes. This article explores how SGLT2 inhibitors work, the evidence supporting their use for kidney health, and practical considerations for patients and providers.

What Are SGLT2 Inhibitors?

SGLT2 inhibitors are a class of oral medications that block the SGLT2 protein in the proximal tubule of the kidney. By inhibiting this transporter, the drugs prevent approximately 90% of filtered glucose from being reabsorbed into the bloodstream. Instead, excess glucose is excreted in the urine, leading to lower blood glucose levels. The class includes canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. While first approved for type 2 diabetes, their protective effects on the heart and kidneys have expanded their indications. Empagliflozin and dapagliflozin are now approved for heart failure with reduced ejection fraction, and certain agents are approved specifically to slow the progression of CKD in patients at risk.

How SGLT2 Inhibitors Affect Kidney Function

Hemodynamic and Metabolic Effects

SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback. In diabetes, increased glucose reabsorption via SGLT2 reduces sodium chloride delivery to the macula densa, resulting in afferent arteriole vasodilation and elevated glomerular filtration pressure. Blocking SGLT2 increases sodium delivery to the distal tubule, which constricts the afferent arteriole and lowers intraglomerular hypertension. This mechanism reduces hyperfiltration, a key driver of diabetic kidney disease progression. Additionally, the drugs promote weight loss, lower blood pressure, and improve insulin sensitivity, all of which benefit kidney health.

Reduction in Albuminuria

Multiple trials show that SGLT2 inhibitors consistently reduce albuminuria by 30–50% within months of initiation. This reduction persists even as eGFR declines, indicating a direct renoprotective effect. The decrease in protein leakage is thought to reflect improvements in glomerular barrier function and reductions in fibrosis and inflammation. Lower albuminuria is strongly associated with slower progression to end-stage kidney disease.

Anti-Inflammatory and Anti-Fibrotic Actions

Beyond hemodynamic changes, SGLT2 inhibitors exert anti-inflammatory and anti-fibrotic effects. They reduce oxidative stress and lower levels of inflammatory markers such as tumor necrosis factor-alpha and interleukin-6. Animal models show that these drugs suppress transforming growth factor-beta signaling, which plays a central role in renal fibrosis. These pleiotropic effects contribute to sustained kidney protection even after eGFR has declined significantly.

Evidence from Landmark Clinical Trials

CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy)

Published in 2019, the CREDENCE trial was the first dedicated renal outcomes study for an SGLT2 inhibitor. It enrolled patients with type 2 diabetes, eGFR 30 to <90 mL/min/1.73 m², and significant albuminuria (urine albumin-to-creatinine ratio 300–5000 mg/g). Canagliflozin reduced the primary composite outcome of end-stage kidney disease, doubling of serum creatinine, or death from renal or cardiovascular causes by 30%. The benefits were consistent across different levels of baseline kidney function, solidifying the role of SGLT2 inhibitors in diabetic kidney disease.

DAPA-CKD (Dapagliflozin and Chronic Kidney Disease)

The DAPA-CKD trial expanded the evidence to include patients with and without type 2 diabetes. It enrolled adults with eGFR 25–75 mL/min/1.73 m² and albuminuria 200–5000 mg/g. Dapagliflozin reduced the composite of sustained decline in eGFR ≥50%, end-stage kidney disease, or death from renal or cardiovascular causes by 39%. Notably, the benefit was equally strong in the non-diabetic subgroup, demonstrating that SGLT2 inhibitors protect kidneys independent of glycemic control. The U.S. Food and Drug Administration subsequently approved dapagliflozin to reduce the risk of kidney function decline in patients with CKD.

EMPA-KIDNEY (Empagliflozin in Chronic Kidney Disease)

The EMPA-KIDNEY trial, announced in 2022, enrolled over 6,600 participants with CKD (eGFR ≥20 to <45 mL/min/1.73 m², or eGFR ≥45 to <90 with albuminuria). Empagliflozin reduced the composite of progression of kidney disease or death from cardiovascular causes by 28%. The trial included a broad range of kidney disease etiologies, including hypertensive nephrosclerosis, glomerulonephritis, and ischemic nephropathy. Its results further cemented the class-wide effectiveness of SGLT2 inhibitors for kidney protection.

These trials are summarized in guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization, which now recommends SGLT2 inhibitors for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m², as well as for selected patients with CKD without diabetes.

Benefits Beyond Glucose Control

The renoprotective benefits of SGLT2 inhibitors are independent of their glucose-lowering effects. Key additional benefits include:

  • Blood pressure reduction: SGLT2 inhibitors lower systolic blood pressure by 3–5 mmHg through osmotic diuresis and reduced sympathetic nervous system activity. This reduction contributes to lower glomerular pressure and slower CKD progression.
  • Weight loss and metabolic improvements: The caloric loss from urinary glucose excretion leads to modest weight loss (2–4 kg on average) and reductions in visceral adiposity, which further decreases systemic inflammation.
  • Uric acid lowering: SGLT2 inhibition increases uric acid excretion, reducing serum urate levels. Hyperuricemia is an independent risk factor for kidney disease progression, and lowering uric acid may provide additional renal benefits.
  • Cardiovascular protection: SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death, which is particularly important because many CKD patients also have coexisting heart disease.

Patient Selection and Initiation

Not every patient with kidney disease is an appropriate candidate for SGLT2 inhibitors. Current guidelines suggest considering these agents for adults with chronic kidney disease and an eGFR ≥20 mL/min/1.73 m², especially those with albuminuria >200 mg/g. For patients with type 2 diabetes and CKD, SGLT2 inhibitors are recommended as part of first-line therapy regardless of glycemic control. In non‑diabetic CKD, the best evidence supports use in those with eGFR 25–75 mL/min/1.73 m² and significant albuminuria.

Before starting therapy, clinicians should assess volume status, especially in older adults or those on loop diuretics. SGLT2 inhibitors can cause a transient drop in eGFR (the “hemodynamic dip”) of 3–5 mL/min/1.73 m², which stabilizes within weeks and is not a reason to discontinue the drug. However, routine monitoring of eGFR and electrolytes is recommended at 2–4 weeks after initiation and periodically thereafter.

Potential Risks and Important Considerations

Urinary Tract Infections and Genital Mycotic Infections

Because SGLT2 inhibitors increase glucose concentration in urine, they raise the risk of urinary tract infections and genital yeast infections. Most infections are mild and easily treated, but patients should be educated about symptoms. A history of recurrent urinary tract infections is a relative contraindication, and some clinicians avoid these drugs in patients with indwelling catheters.

Dehydration and Hypotension

The osmotic diuresis induced by SGLT2 inhibitors can lead to volume depletion, particularly in patients with pre‑existing dehydration, those taking diuretics, or the elderly. Symptoms such as dizziness and orthostatic hypotension should be monitored. Temporary dose reduction of concomitant diuretics may be necessary, and adequate fluid intake should be encouraged.

Ketoacidosis

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious adverse event associated with SGLT2 inhibitors. Unlike typical DKA, blood glucose levels can be only modestly elevated (<250 mg/dL), delaying diagnosis. Risk is highest in patients with type 1 diabetes, prolonged fasting, severe illness, or excessive alcohol intake. SGLT2 inhibitors are not approved for type 1 diabetes, and caution is advised in any patient with factors predisposing to ketoacidosis.

Acute Kidney Injury

Early reports raised concerns about acute kidney injury with canagliflozin, but large trials and meta-analyses have shown that SGLT2 inhibitors actually reduce the risk of AKI. However, because they affect renal hemodynamics, they should be temporarily withheld during acute illness, surgery, or when volume depletion is anticipated. Resume therapy once the patient is stable.

Monitoring During Therapy

Patients on SGLT2 inhibitors require regular follow-up to ensure safe and effective use. Key monitoring parameters include:

  • eGFR and serum creatinine at baseline, at 2–4 weeks, then every 3–6 months.
  • Urine albumin-to-creatinine ratio every 6–12 months to assess proteinuria response.
  • Serum electrolytes (especially potassium) because SGLT2 inhibitors can mildly increase potassium levels, particularly in patients on renin-angiotensin-aldosterone system blockers.
  • Hemoglobin A1c in patients with diabetes to track glycemic control.
  • Clinical assessment for signs of volume depletion, infection, or ketoacidosis.

In patients with advanced CKD (eGFR <20 mL/min/1.73 m²), SGLT2 inhibitors are not typically initiated, although those already on therapy may continue until dialysis begins. Evidence from EMPA-KIDNEY supports benefit down to eGFR 20–25 mL/min/1.73 m², and ongoing studies are exploring use in dialysis populations.

Conclusion: A Cornerstone of Kidney Protection

SGLT2 inhibitors have transformed the landscape of kidney disease management. By lowering intraglomerular pressure, reducing albuminuria, and combating inflammation and fibrosis, they slow the progression of CKD in patients with and without diabetes. Landmark trials such as CREDENCE, DAPA-CKD, and EMPA-KIDNEY provide robust evidence that these drugs reduce the risk of kidney failure and cardiovascular events. Their benefits extend well beyond glucose control, making them a cornerstone of nephroprotective therapy.

However, proper patient selection, dose adjustment, and vigilant monitoring are essential to mitigate risks such as volume depletion, infections, and ketoacidosis. When used appropriately and under medical supervision, SGLT2 inhibitors offer a powerful tool to preserve kidney function, delay dialysis, and improve quality of life. Patients with chronic kidney disease or type 2 diabetes should discuss with their healthcare provider whether an SGLT2 inhibitor is right for them, weighing the potential benefits against individual risk factors.

For additional details, refer to the FDA safety information on SGLT2 inhibitors, the KDIGO 2024 Clinical Practice Guideline for Diabetes and CKD, and the National Institute of Diabetes and Digestive and Kidney Diseases for patient resources.